Alpha 2.0
Login Register
» Articles » PMID: 36172874

Characterization of Dolutegravir Drug Resistance in Persons Diagnosed with HIV After Exposure to Long-acting Injectable Cabotegravir for Preexposure Prophylaxis

Overview
Journal AIDS
Specialty Infectious Diseases
Date 2022 Sep 29
PMID 36172874
Authors
Amrit Kaur Ahluwalia
Seth Inzaule
Rachel Clare Baggaley
Marco Vitoria
Robin Schaefer
Heather-Marie Ann Schmidt
Michelle Rodolph
Amalia Giron
Michael R Jordan
Affiliations
Soon will be listed here.
Citing Articles

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model.

Bekerman E, Yant S, VanderVeen L, Hansen D, Lu B, Rowe W J Clin Invest. 2023; 133(16).

PMID: 37384413 PMC: 10425210. DOI: 10.1172/JCI167818.

The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.

Henderson M, Schmidt H, Chitembo L, Peralta H, Alaama A, Johnson C AIDS Behav. 2023; 27(11):3755-3766.

PMID: 37351685 PMC: 10589125. DOI: 10.1007/s10461-023-04093-1.

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition.

Fonner V, Ridgeway K, van der Straten A, Lorenzetti L, Dinh N, Rodolph M AIDS. 2023; 37(6):957-966.

PMID: 36723489 PMC: 10090368. DOI: 10.1097/QAD.0000000000003494.